TY - JOUR
T1 - A profile of U.S.-based trials of behavioral and social interventions for HIV risk reduction
AU - Semaan, Salaam
AU - Kay, Linda
AU - Strouse, Darcy
AU - Sogolow, Ellen
AU - Mullen, Patricia Dolan
AU - Neumann, Mary Spink
AU - Flores, Stephen A.
AU - Peersman, Greet
AU - Johnson, Wayne D.
AU - Lipman, Paula Darby
AU - Eke, Agatha
AU - Des Jarlais, Don C.
PY - 2002/7/1
Y1 - 2002/7/1
N2 - We describe 99 (experimental and certain quasi-experimental) U.S.-based trials, reported or published since 1988, of behavioral and social interventions that measured prespecified behavioral and biologic outcomes and aimed to reduce risk for HIV infection. Studies identified through June 1998 by the HIV/AIDS Prevention Research Synthesis project were grouped into 4 risk behavior areas: drug-related (k [number of studies] = 48), heterosexual youth (k = 24), heterosexual adult (k = 17), and same-sex (k = 10). We compared the studies in the 4 areas by variables key to the development, evaluation, and transfer of interventions. Participants comprised injection drug users (43% of studies), drug users out of treatment (29%), African Americans (18%), clinic patients (18%), youth in schools (10%), and drug users in treatment (10%). Most studies were randomized (85%), provided another intervention to the control or comparison groups (71%), and evaluated behavioral interventions (92%). On average, interventions were conducted in 5 sessions (total, 8 hours) during 3 months. The theoretical basis of the intervention was not noted in 57% of the reports. At least one variable from each of the 3 outcome classifications was measured in 8% of the studies: behavioral, biologic, and psychosocial. Distinct profiles exist for the 4 risk areas. Addressing gaps in research and reporting would be helpful for analytical and program activities. This sizable portfolio of evaluated interventions contributes to effectiveness reviews and to considerations of transfer to program practice.
AB - We describe 99 (experimental and certain quasi-experimental) U.S.-based trials, reported or published since 1988, of behavioral and social interventions that measured prespecified behavioral and biologic outcomes and aimed to reduce risk for HIV infection. Studies identified through June 1998 by the HIV/AIDS Prevention Research Synthesis project were grouped into 4 risk behavior areas: drug-related (k [number of studies] = 48), heterosexual youth (k = 24), heterosexual adult (k = 17), and same-sex (k = 10). We compared the studies in the 4 areas by variables key to the development, evaluation, and transfer of interventions. Participants comprised injection drug users (43% of studies), drug users out of treatment (29%), African Americans (18%), clinic patients (18%), youth in schools (10%), and drug users in treatment (10%). Most studies were randomized (85%), provided another intervention to the control or comparison groups (71%), and evaluated behavioral interventions (92%). On average, interventions were conducted in 5 sessions (total, 8 hours) during 3 months. The theoretical basis of the intervention was not noted in 57% of the reports. At least one variable from each of the 3 outcome classifications was measured in 8% of the studies: behavioral, biologic, and psychosocial. Distinct profiles exist for the 4 risk areas. Addressing gaps in research and reporting would be helpful for analytical and program activities. This sizable portfolio of evaluated interventions contributes to effectiveness reviews and to considerations of transfer to program practice.
KW - Behavior change
KW - Drug risk behaviors
KW - HIV intervention
KW - HIV/AIDS prevention
KW - Sex risk behaviors
UR - http://www.scopus.com/inward/record.url?scp=17744413689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17744413689&partnerID=8YFLogxK
U2 - 10.1097/00042560-200207011-00004
DO - 10.1097/00042560-200207011-00004
M3 - Article
C2 - 12107358
AN - SCOPUS:17744413689
SN - 1525-4135
VL - 30
SP - S30-S50
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - SUPPL. 1
ER -